Testing ProAgio for Advanced Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ProAgio for people with advanced or metastatic colorectal cancer. It aims to see if ProAgio can help shrink or slow the cancer when combined with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have colorectal cancer that has spread or cannot be surgically removed.
- You have not had FOLFIRI chemotherapy before.
- You are able to be up and about (ECOG score 0 or 1).
- Your blood counts, kidney and liver function are within certain healthy ranges.
- You are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This Phase 2 trial tests whether bevacizumab plus oxaliplatin and TAS-102 works better and is safe as the first treatment for advanced colorectal (colon/rectum) cancer. You may be asked to meet specific health and blood-test requirements and avoid other cancer treatments during the study.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.